Combined Flucytosine — Amphotericin B Treatment of Cryptococcosis
In a prospective study from May 1971 to November 1973, 20 consecutive patients with a diagnosis of disseminated cryptococcosis were treated for six weeks with a combination of amphotericin B (20 mg/d) intravenously and flucytosine (5-FC) (150 mg/kg/d) orally. Fifteen patients had culturally documented Cryptococcus neoformans meningitis, and three died of infection early in therapy. Of the remaining 12 patients, eight were alive and well eight to 34 months following therapy, and four died of other causes. None of the surviving patients has relapsed.
Hematologic complications developed in nine patients, three of whom had no underlying lymphoreticular disorder or therapy with known cytotoxic agents. Renal insufficiency of mild degree occurred in only six patients.
A shorter period of hospitalisation and reduction in amphotericin B toxicity suggest that combined therapy is a safe and efficacious alternative to other regimens.
KeywordsMinimal Inhibitory Concentration Chronic Lymphocytic Leukemia None None Cryptococcal Meningitis Renal Tubular Acidosis
Unable to display preview. Download preview PDF.
- 2.Utz, J.P. Histoplasma and Cryptococcus meningitis. In Infections of the Nervous System, Proceedings of the Association for Research in Nervous and Mental Disease, 44, 378–392 (1968).Google Scholar
- 5.Grunberg, E., Titsworth, E., Bennet, M. Chemotherapeutic activity of 5-fluorocytosine. Antimicrob.Agents Chemother. 1963. American Society for Microbiology, Ann Arbor, 1964, pp.566–568.Google Scholar
- 7.Utz, J.P., Tynes, B.S., Shadomy, H.J., Duma, R.J., Kannan, M.M., Mason, K.N. 5-Fluorocytosine in human cryptococcosis-Antimicrob.Agents Chemother., 1968, American Society for Microbiology, Ann Arbor, 1969, pp.344–346.Google Scholar
- 8.Clinical data sheet on 5-fluorocytosine. Hoffman-La Roche, Inc., Nutley, N.J. (1969).Google Scholar
- 9.Gale, E.F., Cundliffe, E., Reynolds, P.E., Richmond, M.H., Waring, M.J. The molecular basis of antibiotic action. John Wiley and Sons, New York (1972), pp.140–146.Google Scholar
- 13.Shadomy, S., Shadomy, H.J., McCay, J.A., Utz, J.P. In vitro susceptibility of Cryptococcus neoformans to amphotericin B, hamycin, and flucytosine. Antimicrob.Agents Chemother., 1968. American Society for Microbiology, Ann Arbor, 1969 pp.452–460.Google Scholar
- 15.Shadomy, S. Techniques for bioassay and sensitivity tests: amphotericin B and 5-fluorocytosine. In Laboratory methods in medical mycology. 3rd ed. CDC, PHS, USDHEW, Atlanta.Google Scholar
- 17.Utz, J.P., Duma, R.J., McGehee, R.F., Warner, J.F. Chemotherapy of the systemic mycoses: recent clinical observations. In The Proceedings of the Fifth International Congress of the International Society for Human and Animal Mycology, 1971, pp.295–296.Google Scholar